消費者直接遺伝子検査市場：タイプ、チャネル、機能別-世界予測2025-2030年

消費者直接遺伝子検査市場は、2023年に20億2,000万米ドルと評価され、2024年には23億6,000万米ドルに達すると予測され、CAGR 17.21％で成長し、2030年には61億5,000万米ドルになると予測されています。

消費者直接（DTC）遺伝子検査は、消費者がヘルスケア専門家に直接関与することなく遺伝子検査サービスを利用できるようにするもので、これにより個人は家系、健康リスク、素因に関する洞察を直接得ることができます。このようなサービスの必要性は、パーソナライズされた健康情報や積極的な健康管理に対する消費者の関心の高まりに後押しされています。これらの検査は、家系調査、遺伝性疾患の素因スクリーニング、個人に合わせた食事やフィットネスの計画など、いくつかの領域にわたって応用されています。主なエンドユーザーは、自分の遺伝情報に対してより大きな自律性を求める健康志向の個人、系図学者、ウェルネス志向の企業です。市場成長は、遺伝子研究の進歩、シークエンシング技術のコスト削減、個別化ヘルスケアソリューションに対する消費者の意識と需要の高まりによって大きな影響を受けています。しかし、市場は、データプライバシーをめぐる懸念、規制状況の複雑さ、専門家の指導なしには遺伝子データを誤って解釈する可能性などのハードルにも直面しています。こうした課題にもかかわらず、遺伝子情報の使用に関する消費者教育の拡大、強固なデータプライバシー対策の開発、データ解釈の強化のためのAIの統合には大きな機会があります。企業は、透明性の高いデータ保護プロトコルに投資し、顧客ガイダンスのためにヘルスケア専門家と協力し、包括的な教育イニシアチブを通じて顧客エンゲージメントを強化することで、これらの機会を活用することができます。調査とイノベーションは、検査精度の向上、対象健康状態の拡大、遺伝的洞察を実用的なヘルスケアプランに統合するユーザーフレンドリーなプラットフォームの開発に重点を置くべきです。DTC遺伝子検査市場の性質はダイナミックで消費者主導型であり、急速な技術導入と、既存の限界や市場の需要に対処するためのイノベーションの余地が大きいことが特徴です。倫理的配慮を優先し、信頼性が高く実用的な洞察を提供することに重点を置く企業は、この進化する市場で持続的な成長を遂げるために有利な立場にあると思われます。

市場力学：急速に進化する消費者直接遺伝子検査市場の主要市場インサイトを公開

消費者直接遺伝子検査市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 自分自身のヘルスケアをよりコントロールしようとする消費者のパラダイムシフト
  • ゲノム検査と遺伝性疾患のリスクに対する意識の高まり
  • 高齢化社会の進展と慢性疾患の蔓延
  • 血統や先祖の評価に対する探究心の高まり
• 市場抑制要因
  • 関連する科学的、技術的、臨床的問題
  • 誠実さ、事実への忠実さ、広告の真実性に関する憲法修正第1条の問題
• 市場機会
  • 現在および将来の遺伝子診断のための次世代シーケンサーとバイオチップ
  • 顧客ニーズに応えるオンライン・アプリケーションの開発
• 市場の課題
  • 検査結果の解釈の複雑さ
  • 遺伝学に関する医師の十分な知識の欠如

ポーターの5つの力：消費者直接遺伝子検査市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：消費者直接遺伝子検査市場における外部からの影響の把握

外部マクロ環境要因は、消費者直接遺伝子検査市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析消費者直接遺伝子検査市場における競合情勢の把握

消費者直接遺伝子検査市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス消費者直接遺伝子検査市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、消費者直接遺伝子検査市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨消費者直接遺伝子検査市場における成功への道筋を描く

消費者直接遺伝子検査市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 消費者は自らのヘルスケア管理をよりコントロールしたいというパラダイムシフト
    • ゲノム検査と遺伝性疾患のリスクに関する意識の高まり
    • 高齢化が進み、慢性疾患の罹患率も増加している
    • 血統と祖先の評価に関する探究心の高まり
  • 抑制要因
    • 関連する科学的、技術的、臨床的問題
    • 正直さ、事実への忠実性、広告の真実性に関する憲法修正第1条の問題
  • 機会
    • 現在と将来の遺伝子診断のための次世代シーケンシングとバイオチップ
    • 顧客のニーズに応えるオンラインアプリケーションの開発
  • 課題
    • テスト結果の解釈の複雑さ
    • 遺伝学に関する医師の十分な知識の欠如
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 消費者直接遺伝子検査市場：タイプ別

• ミトコンドリアDNA検査
• 一塩基多型検査
• Y染色体検査

第7章 消費者直接遺伝子検査市場：チャネル別

• オフライン
• オンライン

第8章 消費者直接遺伝子検査市場：機能別

• 祖先と民族
• がん検診
  • 遺伝性がん
    • 血液がん
    • 乳がん
    • 卵巣がん
  • 散発性がん
• 遺伝性疾患キャリアステータス
• 新生児スクリーニング
• 特性
• ウェルネス

第9章 南北アメリカの消費者直接遺伝子検査市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の消費者直接遺伝子検査市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの消費者直接遺伝子検査市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Ancestry.com LLC
• Dante Labs Inc.
• EasyDNA
• FamilyTreeDNA by Gene, Ltd.
• Genesis Healthcare Co.
• Helix OpCo, LLC
• Karmagenes SA
• Living DNA Ltd.
• Mapmygenome
• Merck KGaA
• MyHeritage Ltd.
• Positive Biosciences, Ltd.
• Shuwen Biotech Co. Ltd.
• Vitagene, Inc.
• Xcode Life

LIST OF FIGURES

• FIGURE 1. DIRECT-TO-CONSUMER GENETIC TESTING MARKET RESEARCH PROCESS
• FIGURE 2. DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. DIRECT-TO-CONSUMER GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. DIRECT-TO-CONSUMER GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. DIRECT-TO-CONSUMER GENETIC TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DIRECT-TO-CONSUMER GENETIC TESTING MARKET DYNAMICS
• TABLE 7. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY MITOCHONDRIAL DNA TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY SINGLE NUCLEOTIDE POLYMORPHISM TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY Y CHROMOSOME TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY ANCESTRY & ETHNICITY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY SPORADIC CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY GENETIC DISEASE CARRIER STATUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY NEW BABY SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TRAITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY WELLNESS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 44. CANADA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. CANADA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. CANADA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 47. CANADA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 48. CANADA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 71. CHINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. CHINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. CHINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 74. CHINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 75. CHINA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 76. INDIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. INDIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. INDIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 79. INDIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 80. INDIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 162. ITALY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 163. ITALY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 164. ITALY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 165. ITALY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 166. ITALY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 182. POLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 183. POLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 184. POLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 185. POLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 186. POLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 187. QATAR DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 188. QATAR DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 189. QATAR DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 190. QATAR DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 191. QATAR DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CHANNEL, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY CANCER SCREENING, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM DIRECT-TO-CONSUMER GENETIC TESTING MARKET SIZE, BY HEREDITARY CANCER, 2018-2030 (USD MILLION)
• TABLE 237. DIRECT-TO-CONSUMER GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 238. DIRECT-TO-CONSUMER GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

The Direct-to-Consumer Genetic Testing Market was valued at USD 2.02 billion in 2023, expected to reach USD 2.36 billion in 2024, and is projected to grow at a CAGR of 17.21%, to USD 6.15 billion by 2030.

Direct-to-consumer (DTC) genetic testing allows consumers to access genetic testing services without the direct involvement of healthcare professionals, enabling individuals to obtain insights into ancestry, health risks, and predispositions directly. The necessity for such services is driven by the increasing consumer interest in personalized health information and proactive health management. These tests hold application across several domains, including genealogical research, predisposition screening for hereditary diseases, and personalized diet and fitness planning. The primary end-users are health-conscious individuals seeking greater autonomy over their genetic information, genealogists, and wellness-oriented companies. Market growth is significantly influenced by advancements in genetic research, cost reductions in sequencing technologies, and rising consumer awareness and demand for personalized healthcare solutions. However, the market also faces hurdles such as concerns surrounding data privacy, regulatory landscape complexities, and the potential for misinterpretation of genetic data without professional guidance. Despite these challenges, there lies a substantial opportunity in expanding consumer education on genetic information usage, developing robust data privacy measures, and integrating AI for enhanced data interpretation. Companies can capitalize on these opportunities by investing in transparent data protection protocols, collaborating with healthcare professionals for customer guidance, and enhancing customer engagement through comprehensive education initiatives. Research and innovation should focus on advancing test accuracy, expanding the scope of health conditions covered, and developing user-friendly platforms that integrate genetic insights into actionable healthcare plans. The nature of the DTC genetic testing market is dynamic and consumer-driven, characterized by rapid technological adoption and a significant scope for innovation to address existing limitations and market demands. Companies that prioritize ethical considerations and focus on delivering reliable and actionable insights will be well-positioned for sustained growth in this evolving market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Direct-to-Consumer Genetic Testing Market

The Direct-to-Consumer Genetic Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Paradigm shift among consumers seeking greater control over their own healthcare
  • Rising awareness about genome testing and risk of genetic diseases
  • High aging population coupled with growing prevalence of chronic disorders
  • Increased inquisitiveness about the assessment of lineage and ancestry
• Market Restraints
  • Related scientific, technical, and clinical issues
  • First amendment issues of honesty, fidelity to facts, and truth-in-advertising
• Market Opportunities
  • Next-generation sequencing and bio-chip for present and future genetic diagnosis
  • Development of online applications to serve customer needs
• Market Challenges
  • Complexity of test result interpretation
  • Lack of adequate physician knowledge about genetics

Porter's Five Forces: A Strategic Tool for Navigating the Direct-to-Consumer Genetic Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Direct-to-Consumer Genetic Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Direct-to-Consumer Genetic Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Direct-to-Consumer Genetic Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Direct-to-Consumer Genetic Testing Market

A detailed market share analysis in the Direct-to-Consumer Genetic Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Direct-to-Consumer Genetic Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Direct-to-Consumer Genetic Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Direct-to-Consumer Genetic Testing Market

A strategic analysis of the Direct-to-Consumer Genetic Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Direct-to-Consumer Genetic Testing Market, highlighting leading vendors and their innovative profiles. These include Ancestry.com LLC, Dante Labs Inc., EasyDNA, FamilyTreeDNA by Gene, Ltd., Genesis Healthcare Co., Helix OpCo, LLC, Karmagenes SA, Living DNA Ltd., Mapmygenome, Merck KGaA, MyHeritage Ltd., Positive Biosciences, Ltd., Shuwen Biotech Co. Ltd., Vitagene, Inc., and Xcode Life.

Market Segmentation & Coverage

This research report categorizes the Direct-to-Consumer Genetic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Mitochondrial DNA Testing, Single Nucleotide Polymorphism Testing, and Y Chromosome Testing.
• Based on Channel, market is studied across Offline and Online.
• Based on Function, market is studied across Ancestry & Ethnicity, Cancer Screening, Genetic Disease Carrier Status, New Baby Screening, Traits, and Wellness. The Cancer Screening is further studied across Hereditary Cancer and Sporadic Cancer. The Hereditary Cancer is further studied across Blood Cancer, Breast Cancer, and Ovarian Cancer.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Paradigm shift among consumers seeking greater control over their own healthcare
    • 5.1.1.2. Rising awareness about genome testing and risk of genetic diseases
    • 5.1.1.3. High aging population coupled with growing prevalence of chronic disorders
    • 5.1.1.4. Increased inquisitiveness about the assessment of lineage and ancestry
  • 5.1.2. Restraints
    • 5.1.2.1. Related scientific, technical, and clinical issues
    • 5.1.2.2. First amendment issues of honesty, fidelity to facts, and truth-in-advertising
  • 5.1.3. Opportunities
    • 5.1.3.1. Next-generation sequencing and bio-chip for present and future genetic diagnosis
    • 5.1.3.2. Development of online applications to serve customer needs
  • 5.1.4. Challenges
    • 5.1.4.1. Complexity of test result interpretation
    • 5.1.4.2. Lack of adequate physician knowledge about genetics
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Direct-to-Consumer Genetic Testing Market, by Type

• 6.1. Introduction
• 6.2. Mitochondrial DNA Testing
• 6.3. Single Nucleotide Polymorphism Testing
• 6.4. Y Chromosome Testing

7. Direct-to-Consumer Genetic Testing Market, by Channel

• 7.1. Introduction
• 7.2. Offline
• 7.3. Online

8. Direct-to-Consumer Genetic Testing Market, by Function

• 8.1. Introduction
• 8.2. Ancestry & Ethnicity
• 8.3. Cancer Screening
  • 8.3.1. Hereditary Cancer
    • 8.3.1.1. Blood Cancer
    • 8.3.1.2. Breast Cancer
    • 8.3.1.3. Ovarian Cancer
  • 8.3.2. Sporadic Cancer
• 8.4. Genetic Disease Carrier Status
• 8.5. New Baby Screening
• 8.6. Traits
• 8.7. Wellness

9. Americas Direct-to-Consumer Genetic Testing Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Direct-to-Consumer Genetic Testing Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Direct-to-Consumer Genetic Testing Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Ancestry.com LLC
• 2. Dante Labs Inc.
• 3. EasyDNA
• 4. FamilyTreeDNA by Gene, Ltd.
• 5. Genesis Healthcare Co.
• 6. Helix OpCo, LLC
• 7. Karmagenes SA
• 8. Living DNA Ltd.
• 9. Mapmygenome
• 10. Merck KGaA
• 11. MyHeritage Ltd.
• 12. Positive Biosciences, Ltd.
• 13. Shuwen Biotech Co. Ltd.
• 14. Vitagene, Inc.
• 15. Xcode Life